Joji Suzuki1, Jennifer A Johnson, Mary W Montgomery, Margaret C Hayden, Christin N Price, Daniel A Solomon, Jane M Liebschutz, Jeffrey L Schnipper, Roger D Weiss. 1. Department of Psychiatry, Brigham and Women's Hospital, Boston, MA (JS); Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA (JAJ, MWM, DAS); Harvard Medical School, Boston, MA (MCH); Brigham and Women's Physicians Organization, Boston, MA (CNP); Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA (JML); Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (JLS); Division of Drug and Alcohol Abuse, McLean Hospital, Belmont, MA (RDW).
Abstract
OBJECTIVES: Infective endocarditis (IE) among people who inject drugs is associated with high rates of mortality and repeat episodes of endocarditis. We sought to report on longer-term clinical outcomes of patients with IE who were offered buprenorphine or methadone treatment for opioid use disorder (OUD) at their initial hospital admission. METHODS: Individuals with OUD hospitalized between 2013 and 2015 with IE were included for the retrospective study. The following data were extracted from the medical record: sociodemographic data, mortality, repeat episodes of endocarditis, and evidence of ongoing buprenorphine and methadone treatment. The impact of medication use on mortality and repeat episode of endocarditis was examined using survival analysis. RESULTS: Overall, 26 individuals were included in the study. The mean duration of follow-up was 45.0 months (SD 7.2, range 34.0-56.0). During the index admission, 8 received buprenorphine, 8 received methadone, and 10 declined medications. During the follow-up period, 4 (15.4%) individuals died and 10 (38.5%) individuals experienced a repeat episode of endocarditis. Survival analysis of mortality (log-rank P = 0.066) and repeat episode of endocarditis (log-rank P = 0.86) comparing those who received buprenorphine, received methadone, and declined medication did not differ significantly. CONCLUSIONS: Initiation of medication treatment alone may not be sufficient to impact long-term mortality and rates of repeat episode of endocarditis. More research is needed to identify optimal treatment strategies for people who inject drugs with IE.
OBJECTIVES:Infective endocarditis (IE) among people who inject drugs is associated with high rates of mortality and repeat episodes of endocarditis. We sought to report on longer-term clinical outcomes of patients with IE who were offered buprenorphine or methadone treatment for opioid use disorder (OUD) at their initial hospital admission. METHODS: Individuals with OUD hospitalized between 2013 and 2015 with IE were included for the retrospective study. The following data were extracted from the medical record: sociodemographic data, mortality, repeat episodes of endocarditis, and evidence of ongoing buprenorphine and methadone treatment. The impact of medication use on mortality and repeat episode of endocarditis was examined using survival analysis. RESULTS: Overall, 26 individuals were included in the study. The mean duration of follow-up was 45.0 months (SD 7.2, range 34.0-56.0). During the index admission, 8 received buprenorphine, 8 received methadone, and 10 declined medications. During the follow-up period, 4 (15.4%) individuals died and 10 (38.5%) individuals experienced a repeat episode of endocarditis. Survival analysis of mortality (log-rank P = 0.066) and repeat episode of endocarditis (log-rank P = 0.86) comparing those who received buprenorphine, received methadone, and declined medication did not differ significantly. CONCLUSIONS: Initiation of medication treatment alone may not be sufficient to impact long-term mortality and rates of repeat episode of endocarditis. More research is needed to identify optimal treatment strategies for people who inject drugs with IE.
Authors: Sarah E Wakeman; Joshua P Metlay; Yuchiao Chang; Grace E Herman; Nancy A Rigotti Journal: J Gen Intern Med Date: 2017-05-19 Impact factor: 5.128
Authors: Joon Bum Kim; Julius I Ejiofor; Maroun Yammine; Masahiko Ando; Janice M Camuso; Ilan Youngster; Sandra B Nelson; Arthur Y Kim; Serguei I Melnitchouk; James D Rawn; Thomas E MacGillivray; Lawrence H Cohn; John G Byrne; Thoralf M Sundt Journal: J Thorac Cardiovasc Surg Date: 2016-03-12 Impact factor: 5.209
Authors: Paul Trowbridge; Zoe M Weinstein; Todd Kerensky; Payel Roy; Danny Regan; Jeffrey H Samet; Alexander Y Walley Journal: J Subst Abuse Treat Date: 2017-05-11
Authors: Maria A Corcorran; Jenell Stewart; Kristine Lan; Ayushi Gupta; Sara N Glick; Chetan Seshadri; Kevin J Koomalsingh; Edward F Gibbons; Robert D Harrington; Shireesha Dhanireddy; H Nina Kim Journal: Open Forum Infect Dis Date: 2022-03-29 Impact factor: 4.423
Authors: Laura R Marks; Stephen Y Liang; Michael J Durkin; Marlene Martin; Katie D White; Isaac See Journal: J Addict Med Date: 2020-12 Impact factor: 4.647
Authors: Katelyn F McNamara; Breanne E Biondi; Raúl U Hernández-Ramírez; Noor Taweh; Alyssa A Grimshaw; Sandra A Springer Journal: Open Forum Infect Dis Date: 2021-06-02 Impact factor: 3.835
Authors: Darshali A Vyas; Lucas Marinacci; Benjamin Bearnot; Sarah E Wakeman; Thoralf M Sundt; Arminder S Jassar; Virginia A Triant; Sandra B Nelson; David M Dudzinski; Molly L Paras Journal: Open Forum Infect Dis Date: 2022-03-02 Impact factor: 3.835
Authors: Simeon D Kimmel; Alexander Y Walley; Yijing Li; Benjamin P Linas; Sara Lodi; Dana Bernson; Roger D Weiss; Jeffrey H Samet; Marc R Larochelle Journal: JAMA Netw Open Date: 2020-10-01